Arbutus Biopharma
ABUS
48 hedge funds and large institutions have $26.5M invested in Arbutus Biopharma in 2020 Q1 according to their latest regulatory filings, with 9 funds opening new positions, 17 increasing their positions, 10 reducing their positions, and 18 closing their positions.
5,662% more call options, than puts
Call options by funds: $749K | Put options by funds: $13K
70% more repeat investments, than reductions
Existing positions increased: 17 | Existing positions reduced: 10
0.94% less ownership
Funds ownership: 39.07% → 38.13% (-0.94%)
19% less funds holding
Funds holding: 59 → 48 (-11)
50% less first-time investments, than exits
New positions opened: 9 | Existing positions closed: 18
61% less capital invested
Capital invested by funds: $67.4M → $26.5M (-$40.9M)
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CAC
Cowen and Company
New York
|
+$9.21M |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$6.55M |
| 3 |
Goldman Sachs
New York
|
+$5.01M |
| 4 |
RI
RTW Investments
New York
|
+$3.25M |
| 5 |
HP
Hound Partners
New York
|
+$1.55M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
FCMI
Foresite Capital Management IV
Larkspur,
California
|
-$10.3M |
| 2 |
Jennison Associates
New York
|
-$7M |
| 3 |
Point72 Asset Management
Stamford,
Connecticut
|
-$5.27M |
| 4 |
Norges Bank
Oslo,
Norway
|
-$1.03M |
| 5 |
Bank of New York Mellon
New York
|
-$713K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
51
Simplex Trading
Chicago,
Illinois
| – | -$117K | -43,344 | Closed |
|
|
WG
52
Winton Group
London,
United Kingdom
| – | -$118K | -42,373 | Closed |
|
|
OAM
53
Oxford Asset Management
Oxford,
United Kingdom
| – | -$61K | -22,051 | Closed |
|
|
BFM
54
Boothbay Fund Management
New York
| – | -$59K | -21,261 | Closed |
|
|
PP
55
Paloma Partners
Greenwich,
Connecticut
| – | -$55K | -19,674 | Closed |
|
|
ARTA
56
A.R.T. Advisors
New York
| – | -$30K | -10,780 | Closed |
|
57
Deutsche Bank
Frankfurt Am Main Ge,
Germany
| – | -$4K | -1,742 | Closed |
|
|
CSS
58
Cubist Systematic Strategies
Stamford,
Connecticut
| – | -$2K | -895 | Closed |
|
59
Barclays
London,
United Kingdom
| – | -$1K | -360 | Closed |
|
|
PAM
60
Panagora Asset Management
Boston,
Massachusetts
| – | -$1K | -350 | Closed |
|
ABUS Hedge Fund Activity: Q1 2020 in Review
48 of the 4,539 institutional investors tracked by Wall St. Rank reported a position in Arbutus Biopharma (ABUS) for Q1 2020, worth a combined $26.5M — down 61% from $67.4M a quarter earlier.
Sellers outnumbered buyers: 18 funds closed out of ABUS and 9 opened new positions — a net loss of 9 holders — while 10 trimmed existing stakes and 17 added.
The largest buyer was Cowen and Company, adding an estimated $9.21M. The largest seller was Foresite Capital Management IV, exiting entirely with an estimated $10.3M sold.
- 48 institutional investors held Arbutus Biopharma (ABUS) as of Q1 2020, down from 59 in Q4 2019.
- Funds reported $26.5M of Arbutus Biopharma stock for Q1 2020, down 61% quarter-over-quarter.
- 9 funds opened new Arbutus Biopharma positions in Q1 2020 and 18 closed out, a net change of -9 holders.
- The largest Arbutus Biopharma buyer in Q1 2020 was Cowen and Company, an estimated $9.21M added.
- The largest Arbutus Biopharma seller in Q1 2020 was Foresite Capital Management IV, an estimated $10.3M sold.
Based on aggregated 13F filings for Q1 2020.